

<b>Name of the Issuer:</b>	<b>HEALTHCARE GLOBAL ENTERPRISES LIMITED</b>
----------------------------	--

<b>1 Type of Issue (IPO / FPO)</b>	IPO
<b>2 Issue Size (Rs. Cr)</b>	649.64
- Fresh Issue Size (Rs. Cr)	252.88
- Offer for Sale Component (Rs. Cr)	396.76
<i>Source: Prospectus dated March 22, 2016</i>	
<b>3 Grade of issue along with name of the rating agency</b>	
<b>Name</b>	Not Applicable
<b>Grade</b>	Not Applicable

<b>4 Subscription Level (Number of times)</b>	1.31*
Source: Basis of Allotment as finalized in consultation with the National Stock Exchange of India Limited ("NSE")	
*The above figure is after technical rejections and represents 18,749 valid applications with a total of 39,044,460 equity shares bid (including Anchor Investor Portion)	

<b>5 QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges</b>	
Particulars	%
(i) allotment in the issue <sup>(1)</sup>	30.25%
(ii) at the end of 1st FY (March 31, 2016) <sup>(2)</sup>	50.08%
(iii) at the end of 2nd FY (March 31, 2017) <sup>(2)</sup>	48.71%
(iv) at the end of 3rd FY (March 31, 2018)	61.24%

(1) Source: Basis of Allotment. It excludes pre-issue holding by QIBs and includes allotment to Anchor Investors  
(2) Source: Stock Exchange Website

<b>6 Financials of the issuer</b>			
	(In Rs. Crore)		
Parameters	1st FY (March 31, 2016)	2nd FY (March 31, 2017)	3rd FY (March 31, 2018)
Income from operations	575.9	700.11	830.69
Net Profit for the period	5.45	23.04	16.94
Paid-up equity share capital	85.08	85.71	86.9
Reserves excluding revaluation reserves	451.1	404.37	428.2

<b>7 Trading Status in the scrip of the issuer</b>	
Company's Equity Shares shall be listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE"). The Shares have not been suspended or delisted.	
Particulars	Status
(i) at the end of 1st FY (March 31, 2016)	Frequently traded
(ii) at the end of 2nd FY (March 31, 2017)	Frequently traded
(iii) at the end of 3rd FY (March 31, 2018)	Frequently traded

8 Change in Directors of issuer from the disclosures in the offer document

Particulars	Name of the Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2016)	Nil	Nil
(ii) at the end of 1st FY (March 31, 2017)	Mr. Prakash Parthasarathy	Retired
	Dr. B. S. Ramesh	Appointment
	Dr. Amit Varma	Appointment
(iii) at the end of 1st FY (March 31, 2018)	NA	NA

Source: Stock Exchange Filings

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

10 Status of utilization of issue proceeds

(i) as disclosed in the offer document

(Rs. Crore)

Expenditure Items	Amount	Estimated utilization up to March 31, 2017	Estimated utilization up to March 31, 2018	Estimated utilization up to March 31, 2019
Purchase of medical equipment	42.21	42.21	-	-
Investment in IT software, services and hardware	30.19	5.40	16.11	8.68
Pre-payment of debt	147.05	147.05	-	-
General corporate purposes	19.77	10.00	9.77	-
Issue related expenses	13.66	-	-	-
<b>Total</b>	<b>252.88</b>	<b>204.65</b>	<b>25.89</b>	<b>8.68</b>

Source: Prospectus dated March 22, 2016

(ii) Actual utilization

Expenditure Items	Amount to be financed from Gross Proceeds as disclosed in the offer document*	Amount utilized up to March 31, 2017	Amount utilized up to March 31, 2018	Amount utilized up to March 31, 2019
Purchase of medical equipment	42.21	Nil	-	-
Investment in IT software, services and hardware	30.19	2.55	-	-
Pre-payment of debt	147.05	147.00	-	-
General corporate purposes	19.77	Nil	-	-
Issue related expenses	13.66	NA	-	-
<b>Total</b>	<b>252.88</b>	<b>149.55</b>	<b>-</b>	<b>-</b>

Source: Prospectus dated March 22, 2016, BSE Filing

(iii) Reasons for deviation, if any  
Not Applicable

11 Comments of monitoring agency, if applicable

(a) Comments on use of funds	
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	Since the Net Proceeds of the Fresh Issue is less than Rs. 500 crore, the Company is not required to appoint a monitoring agency.
(c) Any other reservations expressed by the monitoring agency about the end use of funds	

12 Pricing Data

Issue Price (Rs.): 218  
 Designated Stock Exchange: NSE  
 Listing Date: 30-Mar-16

Price parameters	At close of listing day (March 30, 2016)	At close of 30th calendar day from listing day (April 28, 2016) <sup>(1)</sup>	At close of 90th calendar day from listing day (July 27, 2016) <sup>(2)</sup>	As at the end of 1st FY after the listing of the issue (March 31, 2016) <sup>(3)</sup>			As at the end of 2nd FY after the listing of the issue (March 31, 2017) <sup>(3)</sup>			As at the end of 3rd FY after the listing of the issue (March 31, 2018) <sup>(3)</sup>		
				Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange	171.00	184.60	196.55	178.55	211.90	167.45	229.45	264.90	167.00	292.9	352.00	227.40
SNP CNX Nifty	7,735.20	7,847.25	8,615.80	7,738.40	8,844.80	6,825.80	9,173.80	9,218.40	7,516.85	10,113.70	11,171.55	9,075.15
BSE SENSEX	25,338.58	25,603.10	28,024.33	25,341.86	29,094.61	22,494.61	29,620.50	29,824.62	24,523.20	32,968.68	36,443.98	29,241.48

Note:

- (1) 30th calendar day shall be taken as listing date plus 29 calendar days.  
 (2) 90th calendar day shall be taken as listing date plus 89 calendar days.  
 (3) High and Low based on intra day prices  
 (4) Pricing data not disclosed as the relevant fiscal year has not completed

13 Basis for Issue Price

Accounting ratio	As disclosed in the offer document <sup>(1)</sup>	At the end of 1st FY (March 31, 2016) <sup>(2)</sup>	At the end of 2nd FY (March 31, 2017) <sup>(2)</sup>	At the end of 3rd FY (March 31, 2018) <sup>(2)</sup>	
<b>Issuer:</b>					
	Consolidated	0.08	0.17	2.69	2.38
<b>Peer Group:</b>					
EPS	Apollo Hospitals Enterprise Limited	24.43	23.79	20.50	8.44
	Fortis Healthcare Limited	(3.11)	(0.97)	9.19	Not Available
	Narayana Hrudayalaya Limited	(0.88)	0.95	4.10	2.53
	<b>Industry Avg:</b>	NA	NA	NA	NA
	<b>Issuer:</b>				
	Consolidated	2725.00	1,050.29	85.30	123.07
<b>Peer Group:</b>					
P/E	Apollo Hospitals Enterprise Limited	60.08	55.67	56.91	125.91
	Fortis Healthcare Limited	-	-	19.60	Not Available
	Narayana Hrudayalaya Limited	-	300.74	76.46	110.14
	<b>Industry Avg:</b>	60.08	178.20	50.99	NA
	<b>Issuer:</b>				
	Consolidated	0.20%	1.02%	4.70%	3.29%
<b>Peer Group:</b>					
RoNW	Apollo Hospitals Enterprise Limited	10.72%	9.15%	7.96%	1.76%
	Fortis Healthcare Limited	-3.55%	-1.73%	7.59%	Not Available
	Narayana Hrudayalaya Limited	-2.18%	4.56%	8.61%	4.96%
	<b>Industry Avg:</b>	1.66%	4.00%	8.06%	NA
	<b>Issuer:</b>				

	<b>Issuer:</b>				
	Consolidated	36.26	63.02	57.17	59.27
	<b>Peer Group:</b>				
NAV per share	Apollo Hospitals Enterprise Limited	227.87	248.24	257.25	243.98
	Fortis Healthcare Limited	87.46	86.31	121.89	Not Available
	Narayana Hrudayalaya Limited	38.42	43.40	47.12	50.68
	<b>Industry Avg:</b>	NA	NA	NA	NA

**Notes:**

(1) Sourced from Prospectus dated March 22, 2016. Disclosure is based on the consolidated financial information disclosed in the Prospectus for Fiscal 2015.

(2) Disclosure is based on the financial results filed with the Stock Exchange

(3) Information not provided as the relevant fiscal year has not completed

Key ratios for the Company for the three fiscal years stated above shall be calculated as follows:

(i) EPS - Fully diluted EPS as reported by the Company in its Annual Report.

(ii) P/E - Closing Price as of relevant fiscal year end / EPS

(iii) RoNW - Net Profit After Tax / Closing networth (Share Capital + Reserves and Surplus - Miscellaneous expenses)

(iv) NAV per share - Closing Networth / Shares Outstanding as of fiscal year end

**14 Any other material information**

<b>Date of disclosure to Designated Stock Exchange</b>	<b>Announcement</b>
HCG launches state-of-the-art Comprehensive Cancer Centre in Vizag	22-Apr-16
HCG Launches Advanced Comprehensive Cancer Centre in Baroda	7-May-16
Appointed Mr. Yogesh Patel as the Chief Financial Officer of the Company, arising out of the resignation of Mr. Krishnan Subramanian.	12-Aug-16
HealthCare Global Enterprises Ltd has entered in to a Shareholders' Agreement on November 03, 2016, with Pinnacle Hospitals India Private Limited, relating to the Company's investment in HCG Pinnacle Oncology Private Limited, a subsidiary of the Company, setting out the relationship between the parties, their rights, obligations as shareholders in HCG Pinnacle Oncology Private Limited; and other matters in connection therewith.	5-Nov-16
Informed that Company proposed to merge DKR Healthcare Private Limited, a subsidiary of BACC Health Care Private Limited, with BACC Health Care Private Limited, being subsidiaries of the Company	17-Nov-16
Entered into a Joint Venture Agreement on November 22, 2016, with HCG Regency Oncology Healthcare Pvt. Ltd, a subsidiary of the Company and Regency Hospital Limited setting out the relationship between the parties, their rights, obligations as shareholders in HCG Regency Oncology Healthcare Pvt. Ltd; and other matters in connection therewith.	24-Nov-16
Launch of HCG Regency Oncology Centre in Kanpur	17-May-17
Execution of Share Purchase Agreement with Pinnacle Hospitals India Private Limited.	2-Jun-17
Scheme of Amalgamation is to provide for the Amalgamation of HCG Pinnacle Oncology Private Limited (Transferor Company) with HealthCare Global Enterprises Limited	22-Aug-17
Approval of Preferential Issue to Indgrowth Capital Fund I	22-Nov-17
Company entered into definitive agreements providing for a business combination of its Triesta Sciences business unit ("Triesta Sciences"), with Strand Life Sciences Private Limited	3-Jan-18

---

In continuation of the intimation made to the stock exchanges on January 03, 2018, on the execution of Business Transfer Agreement, Share Subscription Agreement and Shareholders Agreement by the Company with Strand Life Sciences, we wish to inform you that, the transaction under the Business Transfer Agreement and the Share Subscription Agreement has been completed.

9-Feb-18

Further, we would like to inform you that Strand Life Sciences has received investments from Taurus QC Investment Holdings Pte Ltd and Healthquad Fund I; and the shareholding of the Company in Strand Life Sciences stands at 38.2% on a fully diluted basis.

---

Regional Director, Ministry of Corporate Affairs, Hyderabad, has approved the Scheme of Amalgamation of DKR with BACC on January 29, 2018 ('the Scheme'). BACC is a subsidiary of the Company, and DKR is a wholly owned subsidiary of BACC.

16-Feb-18

---

Request received from a member of the Promoter Group for reclassification from the Promoter/Promoter Group of HealthCare Global Enterprises Limited.

19-Feb-18

---

Allotment of equity shares on preferential basis.

9-Apr-18

---

Source: Stock Exchange Filings

---